Objectives: To investigate whether Budesonide Easyhaler is a cost -effective treatment option in the Russian Federation, compared to Pulmicort Turbuhaler. MethOds: Information search was conducted in the public domain. Pharmacoeconomic analysis method "cost -effectiveness analysis" and direct cost analysis were performed. Results: The information search performed in the course of this study yielded outcomes of the Budesonide Easyhaler and Pulmicort Turbuhaler therapies in the treatment of asthma that used two effectiveness criteria: improvement in lung function (peak expiratory flow -PEF) and decline the number of asthma exacerbations. These results are described in the publication of T. Vanto 2004. Then was calculated the direct cost of the various medications per patient. Cost analysis was conducted on the cost of basic pharmacotherapy (daily dose -0,4mg), compensation costs for treatment of exacerbations, compensation costs for side effects and adverse reactions. The study had a time frame of one year. The total cost per one patient with asthma amounted to 4 727,79$ to the Budesonide Easyhaler group and 5 507,92$ to the Pulmicort Turbuhaler group. In the last stage, effectiveness parameters were obtained. They made 36 283,87$ and 47 116,55$ for improvement in lung function criterion, 1 477,43$ and 3 059,96$ for decline the number of asthma exacerbations criterion to the Easyhaler and Turbuhaler groups respectively. cOnclusiOns: As a result of the cost -effectiveness analysis was demonstrated that Budesonide Easyhaler therapy was the dominant treatment option, being associated with lower cost per effectiveness unit when improvement in lung function and decline the number of asthma exacerbations were utilized as the effectiveness criterion.
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PRS46 EConomiC EvAluAtion of RESPiRAtoRy mEdiCAtion thERAPy AdhEREnCE CliniC (RmtAC) on ASthmA PAtiEntS in mAlAySiA
Yong YV, Shafie AA Universiti Sains Malaysia, Penang, Malaysia Objectives: To evaluate the long-term cost-effectiveness of RMTAC (an adjunct pharmaceutical asthma management) vs. usual physician care clinic by using decision analytic modelling method. MethOds: A dynamic adherence asthma Markov cohort model was developed. The economic evaluation was based on a lifetime horizon and cycle length of one month, from the healthcare provider's (Ministry of Health) perspective, with the outcomes assessed in cost per QALY gained and cost per hospitalization averted. Probabilities of asthma control-adherence states from RMTAC database, costs from national sources, utilities using standard gamble method on Malaysia's asthma patients, and other inputs from secondary data sources were used to inform the probabilistic model, according to gender and age subgroups. A scenario analysis was conducted to test the structural assumption on follow-up visits after the final treatment visit. Results: In female subgroup, RMTAC management dominates the usual care by having 0.91 (95% CI 0.24 -1.69) QALY gained and 0.58 (95% CI -2.30 -6.23) hospitalization averted, at a lower cost. For male subgroup, the ICERs were RM10 (95% CI -RM14431 -RM8323) per QALY gained and RM18 (95% CI -RM35790 -RM30266) per hospitalization averted. At the willingnessto-pay threshold of RM29000 per an additional QALY gained, the RMTAC intervention is likely to be cost-effective 99% and 57% of the time (for QALY and hospitalization outcome, respectively). The analysis was robust to assumptions of follow-up visits frequency and patients' gender. cOnclusiOns: Implementing RMTAC in Malaysia has high probability of being more cost-effective than the usual care management for both male and female subgroups across all age groups. Further investigation is necessary to ensure that implementing this decision does not exceed the overall national healthcare expenditure. Objectives: Asthma is one of the most common chronic diseases globally. Its symptoms and inadequate control, which may lead to exacerbations, could impact on health related quality of life and health outcomes. The objective is to assess the cost-effectiveness of daily 5 mcg tiotropium combined with conventional treatment (CT) (high-dose inhaled corticosteroids and long-acting beta2 agonists) versus CT alone for the treatment of adult patients with persistent severe asthma in Spain. MethOds: A Markov model was developed with 7 health states, according to severity of exacerbations and asthma control, defined by Asthma Control Questionnaire (ACQ-6) results. A lifetime horizon and a Spanish National Health System perspective were considered, including direct medical costs (pharmacological costs and management costs for each health state). A 3% discount rate was applied to cost and health outcomes. Efficacy data were obtained from 205.416 and 205.417 clinical trials, utility values from the literature, and costs from Spanish National databases. In order to assess the robustness of the model results, probabilistic and deterministic univariate sensitivity analyses (SA) were performed modifying time horizon, discount rate and health state costs. Results: The model evaluated costs and efficacy of each alternative for severe asthma treatment, measured as quality-adjusted life year (QALY) gained. Tiotropium plus CT was associated with 15 QALY gained and € 83,122 costs versus 14.79 and € 80,430 with CT alone. The incremental cost-utility ratio for tiotropium plus CT was € 12,985/QALY. Univariate and probabilistic SA results were robust according to the base case scenario. Tiotropium therapy was a cost-effective alternative in 74.7% of simulations performed. cOnclusiOns: Considering the current Spanish cost-effectiveness Objectives: Umeclidinium/vilanterol (UMEC/VI) is a novel fixed dose combination of a long acting muscarinic (LAMA) and a long acting beta agonist (LABA) agents. The objective of this analysis was to evaluate the incremental cost-effectiveness ratio (ICER) of UMEC/VI compared with Tiotropium (TIO), from the Spanish National Health System (NHS) perspective. MethOds: A previously published linked equations cohort model based on the epidemiological longitudinal study ECLIPSE was used. Patients included were COPD patients with a post-bronchodilator forced expiratory volume in one second (FEV1) < 70% and presence of respiratory symptoms measured with the mMRC dyspnoea scale (mMRC > 2). Treatment effect, expressed as change FEV1 from baseline, was estimated from a 24 week-head-to-head phase III clinical trial comparing UMEC/VI with TIO and was assumed to last 52 weeks following treatment initiation (maximum duration of UMEC/VI clinical trials). Spanish utility values were derived from a published local observational study. Unitary healthcare costs (€ 2015) were obtained from local sources. A 3-year time horizon was selected and 3% discount was applied to effects and costs. Results were expressed as cost/quality adjusted life years (QALY). Univariate and probabilistic sensitivity analysis (PSA) were performed. Results: UMEC/VI produced additional 0.03 QALY and 590€ versus TIO, leading to an ICER of 21,475€ /QALY. According to PSA, the probability of UMEC/VI being cost-effective was 80.3% at a willingness-to-pay of 30,000€ /QALY. cOnclusiOns: UMEC/VI could be considered as a cost-effective treatment alternative compared with TIO in symptomatic COPD patients from the Spanish NHS perspective. Objectives: Tiotropium (TIO), Spiriva Handihaler, is a well-established bronchodilator, LAMA (long-acting anticholinergic), for the treatment of moderate to very severe COPD. Clinical evidence from the SPARK trial suggests that TIO is superior to glycopyrronium (GLY), Seebri Breezhaler, in preventing severe exacerbations. This study assessed the cost-effectiveness of TIO versus GLY for Spain making use of this new clinical evidence. MethOds: A Markov cohort model, with GOLD II -IV patients, was populated with efficacy data from the UPLIFT and SPARK trials as well as Spanish costs, utilities and epidemiological data. Treatment efficacy was modelled as improvements in lung function, quality-adjusted life years and as a lowering of the risk of exacerbations (rate of exacerbations). Relative efficacy of preventing exacerbations differed between treatment cohorts based on data from SPARK. Health and cost outcomes were simulated over an approximate life time horizon, starting from an age of 65 years. Robustness of results was validated in deterministic and probabilistic sensitivity analyses. Results: Over the life-time horizon, patients treated with TIO and GLY accumulated € 41,129 and € 40,063 respectively in direct costs (€ 2014) . TIO generated more QALYs (7.77) compared to GLY (7.52). In incremental terms TIO gained 0.25 QALYs compared to GLY at an incremental cost of € 1,066, resulting in a cost per QALY gained of € 4,281 (cost and health outcomes discounted at 3% per annum). The results were mainly driven by the relative risk of severe exacerbations found in SPARK (RR GLY/TIO: 1.43 CI 1.05-1.97, P 0.025). cOnclusiOns: The results from this study show that TIO is a highly costeffective treatment compared to GLY in moderate to very severe COPD. The cost per QALY is well-below the willingness-to-pay threshold for Spain (€ 30,000).
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PRS44 EConomiC EvAluAtion of flutiCASonE PRoPionAtE/foRmotERol fumARAtE (flutifoRm®) vS flutiCASonE/SAlmEtERol And BudESonidE/ foRmotERol in SPAin
Martínez-Moragón E 1 , Delgado J 2 , Ojeda P 3 , Pérez del Llano L 4 , Antón C 5 , Martín C 5 , Collar JM 6 1 Hospital Dr. Peset, Valencia, Spain, 2 Hospital Virgen Macarena, Seville, Spain, 3 Clínica Dres. Ojeda, Madrid, Spain, 4 Complexo Hospitalario Lucus Augusti, Lugo, Spain, 5 Universidad Francisco de Vitoria, Pozuelo de Alarcón (Madrid) , Spain, 6 Mundipharma Pharmaceuticals, S.L., Madrid, Spain Objectives: To estimate the Cost-Effectiveness of Fluticasone propionate/ Formoterol fumarate (FPF) versus Fluticasone/Salmeterol (FS) and Budesonide/ Formoterol (BF) in the treatment of adult patients with moderate to severe asthma from the perspective of the Society in Spain. MethOds: A Markov model was developed with five asthma health states: successful control, sub-optimal control, outpatient-managed exacerbation, inpatient-managed exacerbation, and death. Time horizon was set at 12 months. Weekly transition probabilities were derived from previous international and Spanish publications. Indirect resources utilization were obtained from a published Spanish study to ascertain healthcare resources utilization, identified as lost-workday-equivalents, and corresponding costs related with treatment of asthma in the year 2014. Effectiveness was expressed as quality-adjusted life years (QALY) gained. The cost-effectiveness was expressed as an incremental cost effectiveness ratio (ICER). Univariate and probabilistic sensitivity analysis (SA) were also applied. Results: FPF drug acquisition cost was lower (20% compared to FS and 30% compared to BF), whilst QALY of the three alternatives compared were very similar. Cost per patient on the FPF cohort yielded € 9,326/year, being the lowest price alternative: -1.5% compared to FS and -2.6% compared to BF. The sub-optimal control health state was the mainstay of costs (80% of total costs) in any of the analyzed alternatives and the scenarios. SA results confirmed the data from the base case scenario. cOnclusiOns: From the Spanish societal perspective in year 2014, FPF produced similar QALY gain at a lower cost when compared with FS and BF in a highly meaningful number of replications and scenarios. FPF may be considered a cost-effective alternative in the treatment of moderate to severe asthma in Spain. The cost savings were mainly due to significant FPF lower price acquisition costs compared to the other two alternatives.
